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Objectives: Functional characterization of the erg1 mutant of ergosterol biosynthesis of Candida
albicans.
Methods: We disrupted the ERG1 gene of C. albicans, which encodes squalene epoxidase (EC
1.14.99.7). Since the disruption of both alleles of ERG1 was lethal, the second allele of a heterozygous
disruptant was placed under the control of a regulable promoter, MET3p, which is repressed by
methionine and cysteine.
Results: The reverse-phase HPLC analysis of sterol, extracted from the conditional mutant strain, showed
a total lack of ergosterol and instead accumulation of squalene. This imbalance in sterol composition led
to defects in growth and increased susceptibilities to drugs including fluconazole, ketoconazole, cyclo-
heximide, nystatin, amphotericin B and terbinafine. Reduced drug efflux activity of the erg1 mutant was
associated with poor surface localization of Cdr1p, suggesting that enhanced passive diffusion and
reduced efflux mediated by the ABC (ATP binding cassette) transporter Cdr1p increases drug suscep-
tibility. Additionally, conditional erg1mutant strains were unable to form hyphae in various media.
Conclusions: Taken together, our results demonstrate that the absence of ergosterol, which is one of
the constituents of membrane microdomains (rafts), has a direct effect on drug susceptibility and
morphogenesis of C. albicans.
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Introduction
The incidence of Candida albicans cells acquiring resistance to
azoles has increased considerably in recent years, which has
posed serious problems in successful chemotherapy of candi-
diasis. Current evidence indicates that multidrug resistance
(MDR) is a multifactorial phenomenon comprising multiple
mechanisms: including failure in drug export by extrusion
pumps such as Cdr1p, Cdr2p [ATP binding cassette (ABC)
family] and Mdr1p (major facilitator family), alterations in the
azole-target Erg11p, as well as up-regulation of the encoding
ERG11 gene.1 – 3 A combination of different resistance mechan-
isms has been reported to be responsible for fluconazole resist-
ance in clinical isolates of C. albicans.4
The important role of lipids in drug susceptibilities of
Candida cells has become apparent from recent studies.5 – 7
Azole-resistant C. albicans isolates exhibit altered membrane
phospholipid and sterol composition.6,8 – 10 We and others have
observed that ABC transporters Cdr1p of C. albicans and Pdr5p
of Saccharomyces cerevisiae are particularly sensitive to
changes in lipid composition where functions mediated by these
drug extrusion pump proteins are affected.5,11,12 Taken together,
it appears that the associated changes in membrane lipid compo-
sition (phospholipid/ergosterol), its order (fluidity), and asymme-
try could be important determinants of drug susceptibilities of
yeast cells.6,7
Among various classes of lipids in C. albicans, membrane
ergosterol is an important constituent, which is also the target of
..........................................................................................................................................................................................................................................................................................................................................................................................................................
*Corresponding author. Tel: +91-11-2670-4509; Fax: +91-11-2671-7081; E-mail: rp47@mail.jnu.ac.in
†Both authors contributed equally to this work.
‡Present address. Department of Biochemistry, RWJMS Research Building, UMDNJ, 683 Hoes Lane West, Piscataway, NJ 08854, USA.
..........................................................................................................................................................................................................................................................................................................................................................................................................................
Journal of Antimicrobial Chemotherapy (2005) 55, 905–913
doi:10.1093/jac/dki112
Advance Access publication 21 April 2005
JAC
905
q The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please e-mail: journals.permissions@oupjournals.org
 by guest on M
ay 8, 2011
jac.oxfordjournals.org
D
ow
nloaded from
 
common antifungals like polyenes and azoles.13 – 15 Ergosterol is
also responsible for membrane rigidity, stability and resistance
to physical stresses. In addition, ergosterol modulates membrane
fluidity, permeability and the activities of membrane-bound
enzymes.16 Interestingly, the action of antifungals is affected by
the changes in membrane lipid composition in general and by
ergosterol in particular.12,16 Because of the relationship between
drug resistance and membrane ergosterol composition, many
genes of the ergosterol biosynthetic pathway of C. albicans such
as ERG3, ERG6, ERG11, ERG24 and ERG26 etc. have been
analysed.14,17 – 19
ERG1 encodes squalene epoxidase (EC 1.14.99.7), which is a
FAD-containing monooxygenase that converts squalene into 2,3-
oxidosqualene.13,20,21 Squalene epoxidase plays a key role in the
synthesis of essential sterol compounds, hence homozygous dis-
ruption of ERG1 was found to have deleterious effects in yeast
cells.22,23 In order to explore the direct involvement of ergosterol
in morphogenesis and drug susceptibility of C. albicans, in this
study, we disrupted one allele of ERG1 and expressed the second
allele under the control of the regulable MET3 promoter.24,25 We
show that conditional suppression of ERG1 of C. albicans
increases its susceptibility to drugs and leads to defects in
hyphae formation. The enhanced susceptibility of the conditional
erg1 mutant to various drugs is linked to increased passive diffu-
sion and reduced efflux of drugs mediated by ABC transporter
Cdr1p, which as a result of imbalance in sterol composition was
poorly localized to the plasma membrane.
Materials and methods
Materials
Media chemicals were obtained from Difco (Detroit, MI, USA) and
HiMedia (Mumbai, India). The drugs cycloheximide, terbinafine,
nystatin, amphotericin B, rhodamine-6G and protease inhibitors
(PMSF, leupeptin, pepstatin A, aprotinin) were obtained from Sigma
Chemical Co. (St Louis, MO, USA). Nourseothricin was obtained
from Werner Bioagents (Jena, Germany). Ranbaxy Laboratories
(New Delhi, India) kindly provided fluconazole, while ketoconazole
was a gift from Dupont (Wilmington, DE, USA).
Bacterial and yeast strains and growth media
Plasmids were maintained in Escherichia coli DH 5a. E. coli was
cultured in Luria–Bertani medium (Difco, BD Biosciences, NJ,
USA), to which ampicillin was added (100 mg/L). C. albicans CAI4,
CAF2-1 and the heterozygous disruptant strains were grown in Yeast
Extract Peptone Dextrose (YEPD) broth or synthetic defined (SD)
medium (Bio 101, Vista, CA, USA).25 To repress the MET3 promo-
ter, the conditional ERG1 mutants were grown in SD medium
supplemented with 0.5 mM each of methionine and cysteine (M/C).
Deletion of ERG1 and chromosomal integration of MET3p-
ERG1
ERG1 of C. albicans CAI4 was disrupted by employing the URA-Blaster
method.26,27 A cassette for the disruption of ERG1 was constructed in
several steps. Firstly, 690 bp of the 50 sequences flanking the start of the
CaERG1 ORF were amplified using primers ERG1disA and ERG1disB
(50-CTAGAGCTCGGATCCGTGTTTACTCATATG-30 and 50-CTA-
GAGCTCGGATCCGGACTGGCACTATTCTC-30: bold, regions of
homology; italics, BamHI). Similarly, 761 bp of the 30 untranslated
sequences were amplified by primers ERG1disC and ERG1disD (50-
CTAGAGCTCTGCAGATTGTAAGATAGAGAG-30 and 50-CTAG-
AGCTCTGCAGGTTCTTTCGTCCC-30: bold, regions of homology;
italics, PstI). PCR fragments were sub-cloned into pUC18, which
resulted in plasmids pSKM3 and pSKM6, respectively. pSKM3 was
digested with BamHI and cloned into the BglII site of pUC18. The PstI
fragment of pSKM6 was inserted into the PstI site of the resulting plas-
mid pSKM53. A plasmid with ERG1 flanking sequences, in the correct
orientation, was obtained (pSKM54). Its SacI–SphI fragment
containing the ERG1 disruption cassette was used to obtain
heterozygous strain DE4 (ERG1/erg1D::hisG-URA3-hisG) by
transformation. URA3 was looped out from DE4 using 5-fluoroorotic
acid (1 mg/mL) and 25 mg/L uridine to obtain DE4.2 (ERG1/erg1D::-
hisG).
To place ERG1 under the control of the MET3 promoter, we fol-
lowed a previously described strategy.25 First, a fragment of 543 bp
corresponding to the 50-end of the ERG1 ORF was amplified by PCR
using the primers ErgN-term (50-GCACACCAATAACTGTG-30)
and DErgStpBglII–HindIII (50-CTTAAGCTTAGATCTAGTCTCT-
CTATCTTAC-30) and cloned into pUC18, resulting in plasmid
pSKM12. The BamHI fragment of pSKM12 was inserted into the
single BamHI site of pCaDis, downstream of the MET3 promoter.24
The resulting plasmid pSKM14 was linearized by NcoI (which cuts
within the ERG1 fragment) and was used to transform the heterozy-
gous strain DE4.2 (ERG1/erg1D::hisG) to obtain the conditional
mutant DE4.2.7 (MET3p-ERG1/erg1D::hisG). Integration of hetero-
zygous and conditional strains was checked by Southern blots.
Tagging of Cdr1p with GFP
To tag CDR1-ORF with GFP, its stop codon was mutated into
a BamHI site. For this, 250 bp of the C-terminal CDR1 ORF
was PCR-amplified using primers CDR29F and CDR30R
(50-ATTTGGTACCATACATTAAATTTGCTGGTGGG-30 and
50-GTTTGGATCCTTTCTTATTTTTTTTCTCTCTGTTACCC-30:
bold, regions of homology; italics, KpnI and BamHI). The PCR
amplicon was digested with KpnI–BamHI (sites introduced into
forward and reverse primers during synthesis). GFP along with
the ACT1 termination sequence and the dominant selection
marker gene SAT1 were taken out by digesting vector pADH1G3
with BamHI–PstI.28 The KpnI–PstI-digested vector backbone of
pCPL51 (2.9 kb) was ligated with KpnI–BamHI-digested C-terminal
CDR1 along with BamHI–PstI-digested GFP-SAT1 fragment to
generate the final plasmid pCPG2. Its 3.5 kb KpnI–SacII fragment
having CT-CDR1-GFP-SAT1-30UTR was used to integrate CAF2-1
and DE4.2.7 at the CDR1 locus. The transformants were selected on
YEPD plates containing 200 mg/L of nourseothricin.28 Transformants
were designated as CAF2-1CDR1GFP and DE4.2.7-CDR1GFP for
further study.
Growth of the mutant strains
C. albicans strains were grown for 20 h in SD medium with 0.5 mM
methionine and 0.5 mM cysteine and their growth was monitored at
600 nm after regular time intervals. The growth of the conditional
strains was found to be maximally suppressed at 14 h after the
addition of M/C, and cells at this time point were collected and used
for further analysis.
Identification of sterols by HPLC
Ergosterol formation and squalene accumulation were determined
by reverse-phase HPLC using an HPLC system (Biologic
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Duo-Flow, Bio-Rad, UK). Sterols were extracted by the alcoholic
KOH method7 and reverse-phase chromatography was carried out
using a C-18 column fitted with a C-18 guard column. Elution was
carried out using the previously described gradient program.7,29
Samples were injected as solutions in 95% ethanol. Elution of com-
pounds was automatically monitored by absorption at 214, 230, 260
and 282 nm. Ergosterol and squalene were used as standards (from
Sigma) for comparison of their respective retention times.
Drug susceptibility testing in C. albicans strains
As a result of the exhaustion of methionine and cysteine after 18 h
in the growth medium, it was not possible to determine the MICs of
drugs and therefore only spot assays were performed for testing
drug susceptibilities of the conditional erg1 mutant strain. In spot
assays, 5mL of 5-fold serial dilutions of each yeast culture
(A600 = 0.1) was spotted on to SD plates supplemented with and
without 0.5 mM methionine and 0.5 mM cysteine, in the absence
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Figure 1. (a) Genomic configuration of the C. albicans ERG1 wild-type locus and its deleted derivatives. (b) Southern blot to confirm the disruption of the
first ERG1 allele and orientation of the MET3 promoter upstream of the second allele. Genomic DNA (2mg) from each strain was extracted and digested with
HindIII, blotted and probed with the 1 kb fragment indicated by asterisks in the figure. Strains tested were: lane 1, CAF2-1 (ERG1/ERG1); lane 2, DE4
(ERG1/erg1D::hisG-URA3-hisG); lane 3, DE4.2 (ERG1/erg1D::hisG); and lanes 4 and 5, DE4.2.5/DE4.2.7 (MET3p::ERG1/erg1D::hisG). (c) Growth of the
C. albicans and its erg1 mutant. Cells were tested for growth at 308C in SD medium containing 0.5 mM of methionine and cysteine (M/C). Cells were inocu-
lated to an initial OD600 of 0.1 in SD medium containing M/C. The growth was monitored at regular intervals at OD600. Filled symbols represent growth of
CAF2-1 without M/C (filled circles), CAF2-1 with M/C (filled diamonds), DE4.2.7 without M/C (filled triangles), and DE4.2.7 with M/C (filled squares).
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(control) and in the presence of the drugs. Growth differences were
recorded following incubation of the plates for 2 days at 308C.
Passive diffusion and rhodamine 6G (R6G) efflux
Passive diffusion and efflux of fluorescent R6G was determined
using a protocol described previously,6,7 except that SD medium
supplemented with M/C was used for culturing cells. Cells were
pelleted down and a 2% cell suspension was made in de-energiza-
tion phosphate-buffered saline (PBS) containing 5 mM 2,4-dinitro-
phenol and 5 mM deoxy-D-glucose and incubated for 2 h at
308C.6,7,12 Cells were then washed and incubated in PBS containing
10mM R6G. For passive diffusion, a 1 mL aliquot was taken out at
different time intervals, centrifuged at 9000 g for 2 min and the opti-
cal density of the supernatant was determined at 527 nm.6,7 Efflux
was initiated by the addition of 1 mole of glucose and an aliquot of
1 mL was taken out at regular intervals for measuring optical density
at 527 nm.
Plasma membrane preparation and western blotting
Plasma membranes (PM) were prepared as described previously,30
except that SD medium without (control) and with M/C was used
for cell culture. Western blotting was done with anti-Cdr1p and
anti-Pma1p antibodies.30 PM proteins were separated on an 8%
SDS/polyacrylamide gel and electroblotted onto a nitrocellulose
membrane and incubated with rabbit anti-Cdr1p antibody (diluted
1:500) and rabbit anti-Pma1p antibody (diluted 1:10 000). Proteins
on immunoblots were detected using the chemiluminescence assay
system (ECL kit; Amersham Biosciences).30
GFP fluorescence microscopy
The cells were grown in SD medium with and without M/C, placed
on glass slides and directly viewed under a 100 oil immersion
objective of a confocal microscope (Radiance 2100, AGR, 3Q/BLD,
Bio-Rad, UK).
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Figure 2. Sterol profiling of the wild-type strain and ERG1/erg1 conditional mutants. Sterols were extracted by the alcoholic KOH method as described
previously,7 and were analysed by reverse-phase HPLC. Elution of compounds was automatically monitored by absorption at 214, 230, 260 and 282 nm.7
Ergosterol and squalene were used as standards for comparison of their respective retention times with extracted sterols from Candida cells. The retention
time of ergosterol is 40 min and that of squalene is around 50 min.
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Hyphal morphogenesis in mutant strains
Strains were grown for 5 days at 378C on solid Lee’s and Spider
media.25 Additionally, hyphal-inducing liquid media supplemented
with 15% serum and N-acetyl glucosamine supplemented with
0.50 mM of M/C were also used.31 Following incubation, the colo-
nies and cells were checked for hyphae formation under a Zeiss
Axioscope microscope.
Results and discussion
ERG1 is an essential gene
For the disruption of ERG1, which encodes squalene epoxidase,
a key enzyme of ergosterol biosynthesis, C. albicans sequence
data were obtained from the Stanford Genome Technology
Centre (http://sequence.stanford.edu/group/candida). The
deduced C. albicans Erg1 protein contains 496 residues, with a
predicted molecular mass of 55.3 kDa.20 The genomic region of
ERG1 was isolated by PCR using genomic DNA of the CAI4
strain. A SacI–SphI fragment from plasmid pSKM54 containing
an ERG1 disruption cassette was used to transform the CAI4
strain to obtain heterozygous strain DE4 (ERG1/erg1D::hisG-
URA3-hisG). Heterozygous ERG1/erg1 strains were generated
without any difficulty but construction of the homozygous erg1/
erg1 strain using the same hisG-URA3-hisG blaster cassette
repeatedly failed. This suggested that probably similar to the
ScERG1 gene of S. cerevisiae, CaERG1 of C. albicans is an
essential gene.23
To reconfirm this, we put the second allele under the control
of the MET3 regulable promoter, which is repressed by M/C.24,25
The cells with one ERG1 allele under the control of the
regulable promoter were designated as DE4.2.7 (MET3p-
ERG1/erg1D::hisG) (Figure 1a). Correct integrations in heterozy-
gous and conditional strains were checked by Southern blot, as
shown in Figure 1(b). Two independent clones were picked and
analysed simultaneously for the phenotypes described below.
Pairs of isogenic mutant strains were identical in all phenotypes -
tested.
Growth of the conditional mutant strain is suppressed
The conditional mutant strain DE4.2.7 (MET3p-ERG1/erg1D::
hisG) was grown in liquid SD medium with or without M/C. We
observed that 0.5 mM of M/C was enough to considerably sup-
press the growth of the conditional mutant DE4.2.7, while
growth of the wild-type CAF2-1 and heterozygous strain DE4
remained almost unaffected under similar repressing conditions
(Figure 1c). However, growth suppression ceased after 24 h and
conditional mutants with suppressor were found to regain their
growth. Of note, strain DE4.2.7, when streaked on SD plates
containing 0.5 mM M/C, continued to show suppression of
growth and no regrowth was observed. The regrowth of
conditional strain at 24 h could be because of the leakiness of
the MET3 promoter as was reported previously,32 or partly could
be due to exhaustion of M/C.
ERG1 conditional mutant strain lacks ergosterol
Mutants of the ergosterol biosynthetic pathway do not produce
ergosterol and utilize sterol intermediates to compensate for
the loss of ergosterol.5,8 To confirm the status of ergosterol
levels in the erg1 mutant strain, reverse-phase HPLC was
employed.7,29 The HPLC analyses of extracted sterols revealed
that ergosterol levels in the heterozygous strain DE4 were
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Figure 3. Drug susceptibility tests. In spot assays, 5mL of 5-fold serial
dilutions of each yeast culture (A600 = 0.1) was spotted onto SD plates con-
taining the following drugs: fluconazole (FLC) (10 mg/L), cycloheximide
(CYH) (500 mg/L), ketoconazole (KTC) (0.05 mg/L), terbinafine (TRB)
(0.1 mg/L), nystatin (NYT) (1.25 mg/L), amphotericin B (AMB) (0.2 mg/L),
in the presence or absence of M/C. Growth differences were recorded follow-
ing incubation of the plates for 2 days at 308C.
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Figure 4. Transport of rhodamine 6G (R6G). For passive diffusion, de-ener-
gized cells were incubated with 10mM R6G at 308C, and at different time
points, cells were rapidly centrifuged and the extracellular concentration of
R6G in the supernatant was determined spectrophotometrically at 527 nm.7
Active efflux was initiated by the addition of 1 mole of glucose at the indi-
cated time to de-energize cells.7 The symbols represent the extracellular
amount of R6G in CAF2-1 (filled circles), CAF2-1 (M/C) (filled diamonds),
DE4.2.7 (no M/C) (filled triangles) and DE4.2.7 (M/C) (filled squares). The
inset shows R6G efflux at 25 min post-glucose addition.
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lower compared with the wild-type CAF2-1. Interestingly, the
conditional disruptant strain (DE4.2.7), after growth in the
presence of M/C, showed no detectable characteristic ergos-
terol peak with a retention time of 40 min, but instead showed
a high peak of squalene at a retention time of 50 min
(Figure 2). Thus, HPLC analysis revealed that DE4.2.7 strain,
which conditionally lacks functional squalene epoxidase
(Erg1p), is unable to synthesize ergosterol and instead
accumulates squalene (Figure 2). The lack of ergosterol in the
conditional strain was also confirmed by spectrophotometric
analysis of extracted sterols (data not shown).7 Both the quan-
titative methods thus confirmed that the conditional strain in
the presence of M/C does not synthesize ergosterol and instead
accumulates squalene.
ERG1 expression levels affect drug susceptibility
In view of the fact that alterations in lipid composition affect
drug susceptibilities,6,7,11,33 we examined whether the depletion of
ergosterol and concomitant accumulation of squalene affected
drug susceptibilities of conditional disruptant cells. Interestingly,
under repressing conditions in serial dilution spot assays,
the DE4.2.7 cells were hypersusceptible to all tested drugs
(fluconazole, cycloheximide, ketoconazole, amphotericin B,
nystatin and terbinafine) compared with CAF2-1 and heterozy-
gous DE4.2 (Figure 3). The increased susceptibility of DE4.2.7
conditional mutant cells to terbinafine needs special mention.
Terbinafine is known to target ERG1, therefore, its conditional
disruption, as in DE4.2.7 cells, should result in resistance rather
Figure 5. (a) Expression of Cdr1p. Plasma membrane (PM) fractions from CAF2-1, CAF2-1 (M/C), DE4.2.7 and DE4.2.7 (M/C) were prepared as described
previously.30 PM protein (40mg) was separated on an 8% SDS/polyacrylamide gel, electroblotted onto nitrocellulose membrane and incubated with rabbit
anti-Cdr1p antibody (diluted 1:500) and rabbit anti-Pma1p antibody (diluted 1:10 000). Proteins were detected using an ECL kit.30 Fractions of strain CAF2-1
(lane 1), CAF2-1 with M/C (lane 2), DE4.2.7 without M/C (lane 3) and DE4.2.7 with M/C (lane 4) were analysed. Pma1p was used as the loading control.
(b) DE4.2.7 cells producing Cdr1p-GFP were grown in SD medium with and without M/C and viewed directly by confocal microscopy. The left-hand panels
show the fluorescence images and the right-hand panels show the corresponding phase contrast images. GFP fluorescence from CAF2-1/CDR1-GFP shows
rimmed localization of Cdr1p on the plasma membrane both without and with methionine and cysteine, whereas those of DE4.2.7/CDR1-GFP without and
with M/C result in a patchy appearance with more fluorescence inside the cells.
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that hypersusceptibility. However, our observations support pre-
vious reports in Candida glabrata,22 where an erg1 defect led to
increased susceptibility to terbinafine. These results imply that
various unidentified factors could also modulate the response of
fungal cells to this allylamine.13,23,34 Interestingly, the erg1 con-
ditional strain DE4.2.7 became susceptible to polyenes, nystatin
and amphotericin B, even in the complete absence of detectable
ergosterol (Figure 3). This finding was unexpected, because
polyenes specifically interact with ergosterol and hence erg1
mutants lacking ergosterol are expected to be resistant to these
drugs. Our results support increasing evidence suggesting that
membrane lipids other than ergosterol could also influence poly-
ene susceptibility.13,23,34
erg1 conditional mutants show reduced passive diffusion and
efflux of R6G
Both the entry (passive diffusion) and exit (efflux) of drugs
affect the drug susceptibilities of Candida cells.6,7 We therefore
examined this aspect by measuring passive diffusion and energy-
dependent efflux of R6G, which is a substrate of Cdr1p of
C. albicans.7 The conditional erg1 knockout strain DE4.2.7, in
the presence of M/C, displayed decreased amounts of extracellu-
lar R6G in de-energized cells, suggesting increased passive
diffusion of the substrate (Figure 4). To determine active drug
efflux, the fluorescent compound R6G was allowed to equilibrate
in de-energized Candida mutant cells by passive diffusion and
the energy-dependent extrusion of R6G was then initiated by the
addition of glucose. As depicted in Figure 4, reduction in
glucose-induced efflux, indicated by a decrease in extracellular
concentration of R6G, was seen in conditional mutant strain
DE4.2.7 (70% reduction in efflux of R6G at 25 min after the
addition of glucose, compared with the CAF2-1 cells; see inset
of Figure 4). Thus, the increase in passive diffusion and reduced
ability to efflux, both probably contribute to hypersusceptibility
of the conditional erg1 mutant. Here we would like to mention
that the conditional mutant without the suppressors, which is
similar to the heterozygous strain, showed similar growth to the
wild-type cells. This erg1/ERG1 conditional strain without M/C
could already show the difference in its ability to efflux R6G.
This gene dosage-dependent reduction in efflux in ERG1/erg1
implies that efflux changes are not growth-dependent. Thus
addition of M/C which further reduces the efflux of the
erg1/erg1 strain is due to suppression of the second allele and
not due to the slow growth.
Localization of membrane-bound transporter Cdr1p is
impaired
We have previously observed that the ABC transporter Cdr1p is
selectively sensitive to changes in lipid composition.6,7 It is thus
possible that the observed impaired efflux in the conditional
mutant strain could be due to poor functionality of Cdr1p. Our
immunoblot results revealed that in DE4.2.7 cells, which were
collected after 14 h of M/C addition in SD medium, the
expression of Cdr1p in PM was decreased compared with PM
isolated from the wild-type strain (Figure 5a).
Figure 6. Filamentation of erg1 mutants. Strains tested are designated as CAF2-1 (ERG1/ERG1), the heterozygous strain DE.4 (ERG1/erg1D::hisG-URA3-
hisG) and two independent conditional mutants DE4.2.5 and DE4.2.7 (MET3p::ERG1/erg1D::hisG). (a) Strains were grown on solid Spider and Lee’s media at
378C for 5 days. Colony phenotypes were recorded microscopically (magnification 2.5-fold). (b) Hyphal induction in liquid media by using 15% serum and
N-acetyl glucosamine (with M/C for the conditional mutant) and incubating for 12 h at 378C.31 Cells were seen microscopically at 100 magnification.
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In another set of experiments, we expressed Cdr1p as a GFP-
tagged protein by integrating the CDR1-GFP cassette at the
CDR1 locus by exploiting the SAT1 marker,28 in both wild-type
and DE4.2.7 cells. Confocal microscopic images confirmed that
GFP-tagged Cdr1p was poorly localized on the membrane of the
conditional mutant strain, if grown under repressing conditions.
Typical rimmed fluorescence appearance of Cdr1p-GFP was seen
in CAF2-1, whereas DE4.2.7, under repressing conditions showed
more intracellular fluorescence (Figure 5b). Localization of
Cdr1p-GFP produced in strain CAF2-1 was not affected by the
presence or absence of M/C (Figure 5b). These results indicate
that the absence of ergosterol and/or the accumulation of squa-
lene lead to poor surface localization of Cdr1p in erg1 conditional
mutants and, consequently, to poor efflux of drugs.
Hyphal morphogenesis requires wild-type ERG1 expression
levels
The availability of a conditional strain, in which ERG1
expression could be suppressed, provided an opportunity to
examine if it affects morphogenesis of C. albicans. The ability
of erg1 disruptants to form hyphae was checked on solid Lee’s
and Spider media. Additionally, hyphal-inducing liquid media
supplemented with 15% serum and N-acetyl glucosamine sup-
plemented with 0.50 mM of M/C were also used.31 As compared
with CAF2-1, the heterozygous strain DE4 was found to have
reduced formation of hyphae, while the conditional disruptant
strain DE4.2.7 (erg1/erg1) appeared as colonies lacking fila-
ments and thus had completely lost its ability to form hyphae
under the conditions tested (Figure 6a and b). The inability of
the conditional disruptant strain to form hyphae in all the tested
media suggests that wild-type Erg1p-levels are critical for mor-
phogenesis of C. albicans (Figure 6). Of note, both media used
for hyphal induction already contained M/C and complex
sources of nitrogen, therefore, no additional repressor to the
hyphal media was necessary to partially suppress ERG1
expression, while still permitting growth.25
Conclusions
In conclusion, we demonstrate that any imbalance in sterol com-
position severely increases drug susceptibility of C. albicans
cells. The complete lack of ergosterol in the conditional erg1
mutant and/or accumulation of squalene therein affect function-
ing of the ABC drug extrusion pump protein Cdr1p mainly
because of its poor surface localization. There have been pre-
vious reports describing the role of ergosterol in the morphogen-
esis of Candida,35,36 but in this study, we show a direct link
between sterol composition and the ability of Candida cells to
form hyphae. In this context, it is important to refer to a recent
report, where the presence of polarized membrane domains, rich
in ergosterol and sphingolipid in C. albicans, was demon-
strated.37 Both ergosterol and sphingolipids are two major con-
stituents of membrane microdomains (membrane rafts) and
blocking synthesis of either of the two results in defects in
hyphae formation and drug susceptibilities.7 Considering recent
reports, it appears that Cdr1p of C. albicans may preferentially
be associated with raft microdomains6,7 that remain to be demon-
strated experimentally.
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